Oral Alternative to Ozempic May Be Even More Effective For Weight Loss

Phase 3 trial enrolled 1,698 adults with type 2 diabetes in a 52-week phase 3 trial, phase 3 trial lasting 52 weeks with 1,698 adults with type 2 diabetes across six countries.

Orforglipron reduced HbA1c by 1.71–1.91% from baseline, orforglipron reduced average HbA1c by 1.71–1.91 percentage points from a baseline of 8.3% after 52 weeks.

Oral semaglutide reduced HbA1c by 1.47%, oral semaglutide reduced HbA1c by 1.47% in the same trial.

Orforglipron produced greater average weight loss than oral semaglutide, participants on orforglipron lost an average of 6.1–8.2 kg; those on semaglutide lost 5.3 kg on average.

Caused gastrointestinal side effects in a higher percentage of participants than oral semaglutide, about 59% of participants on orforglipron reported gastrointestinal side effects versus 37–45% on semaglutide.